echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Drug regulatory bureau clarified that 70% of drug distribution enterprises will be eliminated due to misreading

    Drug regulatory bureau clarified that 70% of drug distribution enterprises will be eliminated due to misreading

    • Last Update: 2013-04-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    April 24, 2013 source: economic reference newspaper "70% of drug distribution enterprises have been eliminated, which is a misreading of policies." Relevant personnel of the State Food and Drug Administration (hereinafter referred to as the State Food and Drug Administration) pointed out at the 23 China Pharmaceutical Industry Development Summit Forum that the State Food and drug administration did not take the elimination of many enterprises as the implementation goal of the new drug GSP, but adjusting the structure and reducing the number of enterprises are the collective policies of the drug regulatory authorities On June 1, the newly revised "drug trade quality management specification" (referred to as the new version of drug GSP) will be officially implemented The relevant personnel pointed out that on the one hand, the implementation of the new GSP will make it more difficult for those enterprises that do not have resource advantages, lack of capacity, relatively backward management and small-scale enterprises to meet the main standards Because the whole standard has been raised, so will the conditions On the other hand, it also gives the advantage enterprises the opportunity to expand the scale, improve the network and expand the market Objectively, the new GSP will promote the concentration of advantageous resources to scale enterprises and standardized enterprises, and will greatly accelerate the industry concentration "A lot of people have come to ask us what to do with the eliminated enterprises." He pointed out that the way out of enterprises is very simple, that is to withdraw from the market According to reports, the market concentration of drug circulation industry is higher than that of drug manufacturers In general, although the concentration is relatively high, the situation of how small and scattered is still not fundamentally changed The latest data shows that the concentration of drug circulation industry has further improved in 2011 The top 100 companies have accounted for 73% of the market share, compared with 60% of the top 20 companies The main business income of the top three drug wholesale enterprises in China has accounted for 42% of the top 100 enterprises "More than 90% of the enterprises want to have less than 20% market share This situation is very embarrassing According to the current data, most SMEs have been unable to maintain " He pointed out that the main reason lies in the following: first, the stock of pharmaceutical companies has exited, and many investors have re entered the circulation field The second is that most of the enterprises survive through the way of passing tickets, affiliation, renting and transferring licenses He believes that in the future, many enterprises will be eliminated by the market, which is also the inevitable result of the development of drug distribution industry From the perspective of the development process of foreign circulation industry, the structure of drug circulation enterprises should be a combination of high-quality services of large enterprises and small and medium-sized enterprises "The individuation and specialization of small and medium-sized enterprises is an inevitable trend, providing socialized, specialized and personalized activities Regional services will become an important part of drug circulation activities, taking on the role of the last kilometer Therefore, small and medium-sized enterprises have their own development space, but those enterprises that only rely on illegal survival will inevitably be eliminated " In addition, the drug transportation outside the industry, a key problem neglected in drug circulation, is basically in the regulatory blind spot The new GSP has brought all the drug storage issues involved in drug circulation into the scope of management, and the state will issue supporting policies to supervise this aspect According to him, more than 80% of drug transportation in China's current drug market is carried out by specialized transportation enterprises and units other than drug production and distribution enterprises "Based on the total circulation of drugs in China last year of 890 billion yuan, 700 billion yuan and 800 billion yuan of drugs are transported outside the industry." He pointed out that this was a big risk We must attach great importance to it Because the transportation outside the industry has neither standard nor management, and the supervision is even blank  
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.